Target Name: PZP
NCBI ID: G5858
Review Report on PZP Target / Biomarker Content of Review Report on PZP Target / Biomarker
PZP
Other Name(s): PZP_HUMAN | pregnancy-zone protein | MGC133093 | C3 and PZP-like alpha-2-macroglobulin domain-containing protein 6 | Pregnancy zone protein | PZP alpha-2-macroglobulin like | CPAMD6 | Pregnancy zone protein precursor

Study of PZP: Potential Therapeutic Targets for Cancer, Neurodegenerative Diseases

PZP (Proproz in hand) is a protein that is expressed in the human placenta and has been shown to play a crucial role in the development and maintenance of placenta-tissue interactions. The placenta is a vital organ that plays a critical role in providing nutrients and oxygen to the developing fetus, and is also responsible for removing waste products from the body. PZP has been shown to regulate a variety of physiological processes that are critical to placenta function, including cell adhesion, migration, and angiogenesis.

Recent studies have also shown that PZP is involved in several diseases, including cancer, neurodegenerative diseases, and developmental disorders. PZP has been shown to promote the growth and survival of cancer cells, and has also been linked to the development of neurodegenerative diseases such as Alzheimer's and Parkinson's. In addition, PZP has been shown to contribute to the development of developmental disorders such as Down syndrome and Fragile X syndrome.

Despite these promising findings, much work remains to be done to fully understand the role of PZP in placenta function and disease. One of the main challenges in studying PZP is its complex structure and the difficulty of studying it in a living organism. Another challenge is the lack of effective therapies that can specifically target PZP.

In this article, we will explore the role of PZP in placenta function and the potential implications of studying it as a drug target or biomarker. We will discuss the current state of research on PZP, including its expression and function in the placenta, its involvement in disease, and the challenges and opportunities in studying it.

The Expression and Function of PZP in the Placenta

PZP is a transmembrane protein that is expressed in a variety of tissues, including the placenta, uterus, and brain. It is a member of the tight junction protein family and is involved in cell-cell and cell-tissue interactions. PZP is typically expressed in the placenta at high levels and is thought to play a critical role in regulating placenta-tissue interactions.

Studies have shown that PZP is involved in several physiological processes that are critical to placenta function. PZP has been shown to regulate cell adhesion by preventing adhesion molecules from interacting with each other and by promoting the formation of tight junctions between cells. This regulation of cell adhesion is critical for the development and maintenance of a stable placenta, which is essential for the growth and survival of the developing fetus.

In addition to regulating cell adhesion, PZP is also involved in regulating the migration of cells in the placenta. Studies have shown that PZP plays a critical role in the migration of trophic cells, which are responsible for providing nutrients and oxygen to the developing fetus. The migration of these cells is critical for the development and maintenance of a healthy placenta, and is also essential for the development of neural tube and the formation of the nervous system.

Another important function of PZP in the placenta is its role in regulating angiogenesis. Angiogenesis is the process by which new blood vessels are formed in the body, and is critical for the growth and development of tissues. PZP has been shown to play a critical role in the regulation of angiogenesis by promoting the formation of blood vessels in the placenta and by regulating the production of angiogenic factors.

The Potential Implications of Studying PZP

The expression and function of PZP in the placenta make it an attractive target for drug development. PZP has been shown to contribute to several diseases, including cancer, neurodegenerative diseases, and developmental disorders. Therefore, studying PZP as a drug target or biomarker has the potential to provide new treatments for these diseases.

For example, PZP has been shown to promote the growth and survival of cancer cells, and is therefore a potential target for cancer therapies. Studies have also shown that PZP is involved in the development of neurodegenerative diseases, including Alzheimer's and Parkinson's. Therefore, studying PZP as a potential biomarker or drug target for these diseases could lead to new treatments for these conditions.

In addition, the regulation of PZP by

Protein Name: PZP Alpha-2-macroglobulin Like

Functions: Is able to inhibit all four classes of proteinases by a unique 'trapping' mechanism. This protein has a peptide stretch, called the 'bait region' which contains specific cleavage sites for different proteinases. When a proteinase cleaves the bait region, a conformational change is induced in the protein which traps the proteinase. The entrapped enzyme remains active against low molecular weight substrates (activity against high molecular weight substrates is greatly reduced). Following cleavage in the bait region a thioester bond is hydrolyzed and mediates the covalent binding of the protein to the proteinase

The "PZP Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about PZP comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets

QARS1 | QDPR | QKI | QPCT | QPCTL | QPRT | QRFP | QRFPR | QRICH1 | QRICH2 | QRSL1 | QSER1 | QSOX1 | QSOX2 | QTRT1 | QTRT2 | Queuine tRNA-ribosyltransferase | R-Spondin | R3HCC1 | R3HCC1L | R3HDM1 | R3HDM2 | R3HDM4 | R3HDML | R3HDML-AS1 | RAB GTPase | RAB10 | RAB11A | RAB11AP2 | RAB11B | RAB11B-AS1 | RAB11FIP1 | RAB11FIP2 | RAB11FIP3 | RAB11FIP4 | RAB11FIP5 | RAB12 | RAB13 | RAB14 | RAB15 | RAB17 | RAB18 | RAB19 | RAB1A | RAB1B | RAB20 | RAB21 | RAB22A | RAB23 | RAB24 | RAB25 | RAB26 | RAB27A | RAB27B | RAB28 | RAB29 | RAB2A | RAB2B | RAB3 GTPase activating protein | RAB30 | RAB30-DT | RAB31 | RAB32 | RAB33A | RAB33B | RAB34 | RAB35 | RAB36 | RAB37 | RAB38 | RAB39A | RAB39B | RAB3A | RAB3B | RAB3C | RAB3D | RAB3GAP1 | RAB3GAP2 | RAB3IL1 | RAB3IP | RAB40A | RAB40AL | RAB40B | RAB40C | RAB41 | RAB42 | RAB42P1 | RAB43 | RAB43P1 | RAB44 | RAB4A | RAB4B | RAB4B-EGLN2 | RAB5A | RAB5B | RAB5C | RAB5IF | RAB6A | RAB6B | RAB6C